Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

RDX013

Small molecule · developed by Ardelyx

Phase 2 Most advanced trial (none active)

ARDX Developer

1 Registered trials

What is RDX013?

RDX013 is a potassium secretagogue, a agent that promotes the secretion of potassium. It is studied in hyperkalemia, a condition of elevated potassium levels in the blood.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Pathways: potassium secretion
Therapy area: Metabolic
Developer: Ardelyx (ARDX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04780841	Phase 2	Hyperkalemia	Completed	ARDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hyperkalemia

More from Ardelyx

Tenapanor FDA approved RDX227675 Phase 2

Sources

ClinicalTrials.gov NCT04780841

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARDX page.

Follow ARDX, the company behind RDX013

See ARDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARDX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z